checkAd
    Regeneron Pharmaceuticals Aktie
    835,80
     
    EUR
    +0,67 %
    +5,60 EUR
    Letzter Kurs 08:43:15 Tradegate
    826,80
     
    EUR
    7 STK
    Geldkurs 10:08:28
    835,00
     
    EUR
    7 STK
    Briefkurs 10:08:28
    ISIN: US75886F1075 · WKN: 881535 · SYM: RGO · USA

    Neueste Nachrichten

    Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
    25.04.24 · globenewswire · Regeneron Pharmaceuticals
    Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
    24.04.24 · globenewswire · Regeneron Pharmaceuticals
    Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
    22.04.24 · globenewswire · Regeneron Pharmaceuticals
    The Law Offices of Frank R. Cruz Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
    17.04.24 · Business Wire (engl.) · Regeneron Pharmaceuticals
    Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
    07.04.24 · globenewswire · Regeneron Pharmaceuticals
    Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
    01.04.24 · globenewswire · Regeneron Pharmaceuticals
    Regeneron Provides Update on Biologics License Application for Odronextamab
    25.03.24 · globenewswire · Regeneron Pharmaceuticals
    High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization
    13.03.24 · globenewswire · Regeneron Pharmaceuticals
    Praluent (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
    11.03.24 · globenewswire · Regeneron Pharmaceuticals
    EYLEA HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet
    08.03.24 · globenewswire · Regeneron Pharmaceuticals
    Dupixent (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
    23.02.24 · globenewswire · Regeneron Pharmaceuticals
    Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
    21.02.24 · globenewswire · Regeneron Pharmaceuticals